Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02032004
Recruitment Status : Completed
First Posted : January 9, 2014
Last Update Posted : December 24, 2020
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast, Inc. )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 29, 2020
Actual Study Completion Date : May 29, 2020